Equities Analysts Offer Predictions for ACTU Q1 Earnings

Actuate Therapeutics (NASDAQ:ACTU) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Actuate Therapeutics in a research note issued on Monday, March 17th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.

Actuate Therapeutics Trading Down 1.5 %

Shares of NASDAQ ACTU opened at $7.35 on Wednesday. The company has a 50-day simple moving average of $8.14 and a 200-day simple moving average of $8.06. Actuate Therapeutics has a 12 month low of $5.51 and a 12 month high of $11.73.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ACTU. BIOS Capital Management LP acquired a new stake in shares of Actuate Therapeutics during the fourth quarter worth $78,753,000. Voss Capital LP acquired a new position in shares of Actuate Therapeutics during the 4th quarter valued at about $440,000. Northwestern University purchased a new position in shares of Actuate Therapeutics during the 3rd quarter worth about $207,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $130,000. Finally, Sigma Planning Corp acquired a new stake in shares of Actuate Therapeutics in the fourth quarter worth approximately $128,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.